YZYu Zhou

Yu Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu Zhou has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoyu Li

    Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong SAR, China

    4 shared publications
  • Yan Cao

    Department of Biochemical Pharmacy, School of Pharmacy, Naval Medical University, Shanghai 200433, China; Shanghai Key Laboratory for Pharmaceutical Metabolite Research, School of Pharmacy, Naval Medical University, Shanghai 200433, China

    3 shared publications
  • Jianzhao Peng

    Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong SAR, China

    2 shared publications
  • Wenyin Shen

    Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong SAR, China

    2 shared publications
  • Yiran Huang

    Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong SAR 999077, China

    2 shared publications
  • Yizhou Li

    Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University, Chongqing, China

    2 shared publications

Latest Publications

  • Open Access

    A γ-AApeptide-Based Antibody-like Peptidomimetic for Enhanced EGFR-Targeted PET Imaging

    by Xiaoyan Li, Yu Yu Win, Yuan Hua, Muhammad Amir, Jason C. Mixdorf, Jonathan W. Engle, Todd E. Barnhart, Yu Zhou, Weibo Cai

    Targeted imaging for the extracellular domain (ECD) of epidermal growth factor receptor (EGFR) is promising for early diagnosis and therapeutic applications toward cancers. Herein, we report the design of a γ-AApeptide-based antibody-like peptidomimetic as a radiotracer for EGFR-targeted positron emission tomography (PET) imaging. A dimeric cyclic γ-AApeptide (D1) was designed by dimerizing a previously reported EGFR-binding peptidomimetic ligand, resulting in a 6-fold enhancement in binding affinity (Kd = 0.11 μM) compared to its monomeric counterpart (M1, Kd = 0.67 μM). Both ligands were conjugated with chelators and radiolabeled with 64Cu to yield [64Cu]Cu-NOTA-M1 (monomer) and [64Cu]Cu-DOTA-D1 (dimer), respectively. In vivo PET imaging demonstrated that [64Cu]Cu-DOTA-D1 achieved significantly higher tumor uptake than [64Cu]Cu-NOTA-M1 in EGFR-positive tumor models (e.g., 10.83 ± 2.70 %ID/g vs 2.80 ± 0.72 %ID/g in U87 tumors at 4 h p.i.). Blocking and EGFR-negative control studies further confirmed the targeting specificity of [64Cu]Cu-DOTA-D1. Ex vivo biodistribution analysis showed consistent enhancement in tumor uptake (e.g., 7.94 ± 0.24 %ID/g vs 3.81 ± 0.44 %ID/g in U87 tumors at 48 h p.i.) for the dimeric tracer, accompanied by increased uptake in clearance organs. Overall, this work demonstrates that cyclic γ-AApeptides could serve as effective antibody-like peptidomimetics for EGFR targeting in vivo and provides a versatile strategy for developing peptidomimetic radiotracers for molecular imaging applications.

  • Agonist Discovery for Membrane Proteins on Live Cells by Using DNA-encoded Libraries

    by Yiran Huang, Rui Hou, Fong Sang Lam, Yunxuan Jia, Yu Zhou, Xun He, Gang Li, Feng Xiong, Yan Cao, Dongyao Wang, et al.

    Identifying biologically active ligands for membrane proteins is an important task in chemical biology. We report an approach to directly identify small molecule agonists against membrane proteins by selecting DNA-encoded libraries (DELs) on live cells. This method connects extracellular ligand binding with intracellular biochemical transformation, thereby biasing the selection toward agonist identification. We have demonstrated the methodology with three membrane proteins: epidermal growth factor receptor (EGFR), thrombopoietin receptor (TPOR), and insulin receptor (INSR). A ∼30 million and a 1.033 billion-compound DEL were selected against these targets, and novel agonists with subnanomolar affinity and low micromolar cellular activities have been discovered. The INSR agonists activated the receptor by possibly binding to an allosteric site, exhibited clear synergistic effects with insulin, and activated the downstream signaling pathways. Notably, the agonists did not activate the insulin-like growth factor 1 receptor (IGF-1R), a highly homologous receptor whose activation may lead to tumor progression. Collectively, this work has developed an approach toward "functional" DEL selections on the cell surface and may provide a widely applicable method for agonist discovery for membrane proteins.


  • Protein-templated ligand discovery via the selection of DNA-encoded dynamic libraries

    by Yu Zhou, Wenyin Shen, Ying Gao, Jianzhao Peng, Qingrong Li, Xueying Wei, Shihao Liu, Fong Sang Lam, Joan Mayol-Llinàs, Guixian Zhao, et al.

    DNA-encoded chemical libraries (DELs) have become a powerful technology platform in drug discovery. Dual-pharmacophore DELs display two sets of small molecules at the termini of DNA duplexes, thereby enabling the identification of synergistic binders against biological targets, and have been successfully applied in fragment-based ligand discovery and affinity maturation of known ligands. However, dual-pharmacophore DELs identify separate binders that require subsequent linking to obtain the full ligands, which is often challenging. Here we report a protein-templated DEL selection approach that can identify full ligand/inhibitor structures from DNA-encoded dynamic libraries (DEDLs) without the need for subsequent fragment linking. Our approach is based on dynamic DNA hybridization and target-templated in situ ligand synthesis, and it incorporates and encodes the linker structures in the library, along with the building blocks, to be sampled by the target protein. To demonstrate the performance of this method, 4.35-million- and 3.00-million-member DEDLs with different library architectures were prepared, and hit selection was achieved against four therapeutically relevant target proteins.


  • 3.2.1.1 Encoding Using Double-Stranded DNA: A Headpiece-Based DNA Ligation Strategy

    by Y. Zhou, Y. Huang, L. Xu, F. Xiong

    DNA-encoded chemical libraries (DELs) provide a powerful high-throughput screening platform that is used in both academia and industry. High-quality DELs lay the foundation for reliable DEL selection outcomes, and most pharmaceutical companies would prefer double-stranded DELs (dsDELs) because of their superior stability. Here, we summarize the experimental details for encoding a dsDEL, including the overall encoding strategy, synthetic chemistry of building-block addition, ligation strategies of code elongation, and quality control of the resulting libraries, exemplified with a 320-million-membered benzimidazole dsDEL from GlaxoSmithKline (GSK). We also briefly review the successful selection cases involving the presented libraries to highlight the great potential of dsDELs in drug discovery.

  • Selection of DNA-encoded chemical libraries against endogenous membrane proteins on live cells

    by Yiran Huang, Ling Meng, Qigui Nie, Yu Zhou, Langdong Chen, Shilian Yang, Yi Man Eva Fung, Xiaomeng Li, Cen Huang, Yan Cao, et al.

    Membrane proteins on the cell surface perform a myriad of biological functions; however, ligand discovery for membrane proteins is highly challenging, because a natural cellular environment is often necessary to maintain protein structure and function. DNA-encoded chemical libraries (DELs) have emerged as a powerful technology for ligand discovery, but they are mainly limited to purified proteins. Here we report a method that can specifically label membrane proteins with a DNA tag, and thereby enable target-specific DEL selections against endogenous membrane proteins on live cells without overexpression or any other genetic manipulation. We demonstrate the generality and performance of this method by screening a 30.42-million-compound DEL against the folate receptor, carbonic anhydrase 12 and the epidermal growth factor receptor on live cells, and identify and validate a series of novel ligands for these targets. Given the high therapeutic significance of membrane proteins and their intractability to traditional high-throughput screening approaches, this method has the potential to facilitate membrane-protein-based drug discovery by harnessing the power of DEL.